What is Iteos Therapeutics, Inc.'s earnings per share (EPS)?

Iteos Therapeutics, Inc. (ITOS) reported diluted earnings per share of $-3.32 for fiscal year 2024. This represents a -5.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Iteos Therapeutics, Inc. Financials

ITOS

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2025 Currency USD FYE December

This page shows Iteos Therapeutics, Inc. (ITOS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ITOS FY2024 2026-04-22

iTeos is being run as a cash-funded development program, with research spending far more important than reported revenue.

FY2024's net loss of -$134.4M and operating cash burn of -$98.2M were directionally aligned, unlike FY2022 when reported profit did not convert into cash; that makes recent results a cleaner read on the business's underlying economics. Even after $122.2M of financing inflow, year-end cash was only $142.1M, so the balance sheet is still funding operations rather than operations rebuilding liquidity.

Current assets of $509.5M versus current liabilities of $40.4M show that near-term bills are well covered, which matters more here than profit margins. But cash runway is finite: year-end cash of $142.1M covered only roughly a year and a half of FY2024 free cash outflow of $99.8M, so liquidity is real but not self-renewing.

Revenue fell to $35.0M in FY2024 from $267.6M in FY2022, which makes the earlier profitable years look more like episodic deal-driven income than a durable sales base. Meanwhile R&D climbed to $145.4M from $97.4M, showing management kept prioritizing development even as recognized revenue became much smaller.

Financial Health Signals

Financial Health Score 34/100

Scored against operating companies for FY2024. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Iteos Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Iteos Therapeutics, Inc. has an operating margin of -455.8%, meaning the company retains $-456 of operating profit per $100 of revenue. This below-average margin results in a low score of 11/100, suggesting thin profitability after operating expenses. This is up from -1199.7% the prior year.

Growth

Iteos Therapeutics, Inc.'s revenue surged 177.9% year-over-year to $35.0M, reflecting rapid business expansion. This strong growth earns a score of 1/100.

Leverage

Iteos Therapeutics, Inc. carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 77/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 12.62, Iteos Therapeutics, Inc. holds $12.62 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 98/100.

Cash Flow

While Iteos Therapeutics, Inc. generated -$98.2M in operating cash flow, capex of $1.6M consumed most of it, leaving -$99.8M in free cash flow. This results in a low score of 3/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Iteos Therapeutics, Inc. generates a -22.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 13/100. This is down from -19.6% the prior year.

Altman Z-Score Grey Zone

2.87

Iteos Therapeutics, Inc. scores 2.87, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($448.7M) relative to total liabilities ($96.7M). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Iteos Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.73x

For every $1 of reported earnings, Iteos Therapeutics, Inc. generates $0.73 in operating cash flow (-$98.2M OCF vs -$134.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$35.0M

YoY+177.9%

Iteos Therapeutics, Inc. generated $35.0M in revenue in fiscal year 2024. This represents an increase of 177.9% from the prior year.

EBITDA

-$158.3M

YoY-5.4%

Iteos Therapeutics, Inc.'s EBITDA was -$158.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 5.4% from the prior year.

Net Income

-$134.4M

YoY-19.3%

Iteos Therapeutics, Inc. reported -$134.4M in net income in fiscal year 2024. This represents a decrease of 19.3% from the prior year.

EPS (Diluted)

$-3.32

YoY-5.4%

Iteos Therapeutics, Inc. earned $-3.32 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 5.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$99.8M

YoY+6.5%

Iteos Therapeutics, Inc. generated -$99.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 6.5% from the prior year.

Cash & Debt

$142.1M

YoY-43.4%

5Y CAGR+48.2%

Iteos Therapeutics, Inc. held $142.1M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

37M

YoY+1.9%

Iteos Therapeutics, Inc. had 37M shares outstanding in fiscal year 2024. This represents an increase of 1.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-455.8%

YoY+743.9pp

Iteos Therapeutics, Inc.'s operating margin was -455.8% in fiscal year 2024, reflecting core business profitability. This is up 743.9 percentage points from the prior year.

Net Margin

-384.0%

YoY+510.3pp

Iteos Therapeutics, Inc.'s net profit margin was -384.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 510.3 percentage points from the prior year.

Return on Equity

-22.8%

YoY-3.2pp

Iteos Therapeutics, Inc.'s ROE was -22.8% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 3.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$145.4M

YoY+28.4%

5Y CAGR+49.9%

Iteos Therapeutics, Inc. invested $145.4M in research and development in fiscal year 2024. This represents an increase of 28.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.6M

YoY-44.9%

5Y CAGR+17.8%

Iteos Therapeutics, Inc. invested $1.6M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 44.9% from the prior year.

ITOS Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$35.0M+177.9%	$12.6M-95.3%	$267.6M-22.4%	$344.8M	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$145.4M+28.4%	$113.3M+16.4%	$97.4M+64.0%	$59.4M+98.6%	$29.9M+55.6%	$19.2M
SG&A Expenses	$49.1M-2.6%	$50.4M+14.7%	$43.9M+8.5%	$40.5M+164.0%	$15.3M+73.6%	$8.8M
Operating Income	-$159.5M-5.6%	-$151.1M-219.6%	$126.3M-48.4%	$244.9M+641.3%	-$45.2M-61.3%	-$28.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$14.1M+289.6%	$3.6M-93.1%	$52.1M+24.2%	$41.9M+73684.2%	-$57K+52.1%	-$119K
Net Income	-$134.4M-19.3%	-$112.6M-216.5%	$96.7M-54.9%	$214.5M+664.0%	-$38.0M-69.4%	-$22.5M
EPS (Diluted)	$-3.32-5.4%	$-3.15-223.0%	$2.56-54.9%	$5.68+297.2%	$-2.88	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$0	N/A	N/A	$0-100.0%	$35.0M	$0	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$57.3M+97.2%	$29.0M	N/A	$36.7M-0.1%	$36.7M+6.3%	$34.5M	N/A	$30.6M
SG&A Expenses	$10.2M-7.3%	$11.0M	N/A	$12.1M-2.8%	$12.5M-1.9%	$12.7M	N/A	$12.6M
Operating Income	-$83.8M-109.4%	-$40.0M	N/A	-$48.8M-244.5%	-$14.2M+70.0%	-$47.2M	N/A	-$43.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$1.7M+51.8%	$1.1M	N/A	$2.2M-0.8%	$2.3M+2.1%	$2.2M	N/A	-$1.2M
Net Income	-$78.7M-127.5%	-$34.6M	N/A	-$45.4M-536.3%	-$7.1M+81.3%	-$38.2M	N/A	-$32.2M
EPS (Diluted)	$-1.81-126.3%	$-0.80	N/A	$-1.05-483.3%	$-0.18+83.2%	$-1.07	N/A	$-0.90

ITOS Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$687.0M+2.9%	$667.6M-11.6%	$755.0M-14.7%	$884.7M+156.8%	$344.6M+1020.7%	$30.7M
Current Assets	$509.5M-7.5%	$550.7M-12.4%	$628.3M-28.2%	$874.7M+157.6%	$339.5M+1202.1%	$26.1M
Cash & Equivalents	$142.1M-43.4%	$251.2M-11.8%	$284.8M-66.4%	$848.5M+152.3%	$336.3M+1592.8%	$19.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$96.7M+4.7%	$92.4M+0.8%	$91.7M-72.4%	$331.9M+1453.7%	$21.4M-68.0%	$66.8M
Current Liabilities	$40.4M+0.9%	$40.0M-4.7%	$42.0M-86.2%	$304.1M+1927.8%	$15.0M+13.7%	$13.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$590.3M+2.6%	$575.2M-13.3%	$663.3M+20.0%	$552.8M+71.0%	$323.2M+995.6%	-$36.1M
Retained Earnings	-$9.8M-107.8%	$124.6M-47.5%	$237.3M+68.7%	$140.6M+290.3%	-$73.9M-106.0%	-$35.9M

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$623.1M-5.4%	$658.9M-4.1%	$687.0M-5.0%	$723.1M-3.8%	$751.8M+19.4%	$629.8M-5.7%	$667.6M-1.5%	$677.6M
Current Assets	$529.0M-1.5%	$537.0M+5.4%	$509.5M-6.5%	$544.9M-13.0%	$626.6M+30.4%	$480.4M-12.8%	$550.7M-11.1%	$619.1M
Cash & Equivalents	$207.8M+32.8%	$156.5M+10.1%	$142.1M+14.9%	$123.7M-50.7%	$251.1M+71.2%	$146.6M-41.6%	$251.2M+23.0%	$204.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$129.3M+35.4%	$95.4M-1.3%	$96.7M+5.8%	$91.4M+3.9%	$88.0M-0.7%	$88.6M-4.1%	$92.4M+16.3%	$79.4M
Current Liabilities	$70.3M+84.9%	$38.0M-5.8%	$40.4M+9.6%	$36.8M+6.2%	$34.7M-2.5%	$35.6M-11.1%	$40.0M+41.8%	$28.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$493.8M-12.4%	$563.4M-4.6%	$590.3M-6.6%	$631.7M-4.8%	$663.9M+22.7%	$541.2M-5.9%	$575.2M-3.9%	$598.3M
Retained Earnings	-$123.1M-177.3%	-$44.4M-353.9%	-$9.8M-128.8%	$33.9M-57.2%	$79.3M+191.8%	-$86.4M-169.3%	$124.6M-19.7%	$155.2M

ITOS Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$98.2M+5.4%	-$103.8M+6.7%	-$111.2M-121.7%	$513.1M+2138.2%	-$25.2M-8.8%	-$23.1M
Capital Expenditures	$1.6M-44.9%	$3.0M+216.2%	$938K-20.6%	$1.2M+231.7%	$356K-50.6%	$721K
Free Cash Flow	-$99.8M+6.5%	-$106.7M+4.8%	-$112.1M-121.9%	$512.0M+2105.2%	-$25.5M-7.0%	-$23.9M
Investing Cash Flow	-$131.2M-280.5%	$72.7M+116.3%	-$446.1M-35814.8%	-$1.2M-229.4%	-$377K+59.3%	-$926K
Financing Cash Flow	$122.2M+10883.0%	$1.1M-43.9%	$2.0M-45.8%	$3.7M-98.9%	$340.3M+1410.0%	$22.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$42.4M-25.7%	-$33.8M-714.2%	$5.5M+114.7%	-$37.4M-10.1%	-$33.9M-4.7%	-$32.4M-135.4%	-$13.8M+59.4%	-$33.9M
Capital Expenditures	$283K+180.2%	$101K-33.6%	$152K+61.7%	$94K-78.7%	$442K-53.2%	$945K-32.3%	$1.4M+85.9%	$751K
Free Cash Flow	-$42.7M-26.2%	-$33.9M-733.6%	$5.3M+114.3%	-$37.4M-8.9%	-$34.4M-3.1%	-$33.3M-119.9%	-$15.2M+56.2%	-$34.6M
Investing Cash Flow	$87.0M+82.3%	$47.7M+250.2%	$13.6M+114.9%	-$91.5M-660.5%	$16.3M+123.5%	-$69.6M-213.1%	$61.6M+171.3%	$22.7M
Financing Cash Flow	$4.5M+13940.6%	$32K-88.8%	$285K+164.5%	-$442K-100.4%	$122.4M+556154.5%	$22K-92.8%	$307K+2970.0%	$10K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ITOS Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-455.8%+743.9pp	-1199.7%-1246.9pp	47.2%-23.8pp	71.0%	N/A	N/A
Net Margin	-384.0%+510.3pp	-894.3%-930.5pp	36.1%-26.1pp	62.2%	N/A	N/A
Return on Equity	-22.8%-3.2pp	-19.6%-34.2pp	14.6%-24.2pp	38.8%+50.6pp	-11.8%	N/A
Return on Assets	-19.6%-2.7pp	-16.9%-29.7pp	12.8%-11.4pp	24.3%+35.3pp	-11.0%+62.0pp	-73.0%
Current Ratio	12.62-1.1	13.76-1.2	14.96+12.1	2.88-19.8	22.64+20.7	1.98
Debt-to-Equity	0.160.0	0.16+0.0	0.14-0.5	0.60+0.5	0.07+1.9	-1.85
FCF Margin	-285.2%+562.2pp	-847.3%-805.4pp	-41.9%-190.4pp	148.5%	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	-40.5%	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	-20.4%	N/A	N/A	N/A
Return on Equity	-15.9%-9.8pp	-6.1%	N/A	-7.2%-6.1pp	-1.1%+6.0pp	-7.1%	N/A	-5.4%
Return on Assets	-12.6%-7.4pp	-5.3%	N/A	-6.3%-5.3pp	-0.9%+5.1pp	-6.1%	N/A	-4.8%
Current Ratio	7.53-6.6	14.13+1.5	12.62-2.2	14.80-3.3	18.08+4.6	13.51-0.3	13.76-8.2	21.94
Debt-to-Equity	0.26+0.1	0.170.0	0.16+0.0	0.14+0.0	0.13-0.0	0.160.0	0.16+0.0	0.13
FCF Margin	N/A	N/A	N/A	N/A	-98.2%	N/A	N/A	N/A

Similar Companies

Replimune Group REPL

$932.6M

Erasca, Inc. ERAS

$6.0B

Alumis Inc ALMS

$3.9B

Corvus Pharmaceu CRVS

$1.4B

Bicycle Therapeutics Limited BCYC

$291.8M

Frequently Asked Questions

What is Iteos Therapeutics, Inc.'s annual revenue?

Iteos Therapeutics, Inc. (ITOS) reported $35.0M in total revenue for fiscal year 2024. This represents a 177.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Iteos Therapeutics, Inc.'s revenue growing?

Iteos Therapeutics, Inc. (ITOS) revenue grew by 177.9% year-over-year, from $12.6M to $35.0M in fiscal year 2024.

Is Iteos Therapeutics, Inc. profitable?

No, Iteos Therapeutics, Inc. (ITOS) reported a net income of -$134.4M in fiscal year 2024, with a net profit margin of -384.0%.

What is Iteos Therapeutics, Inc.'s EBITDA?

Iteos Therapeutics, Inc. (ITOS) had EBITDA of -$158.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Iteos Therapeutics, Inc.'s operating margin?

Iteos Therapeutics, Inc. (ITOS) had an operating margin of -455.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Iteos Therapeutics, Inc.'s net profit margin?

Iteos Therapeutics, Inc. (ITOS) had a net profit margin of -384.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Iteos Therapeutics, Inc.'s return on equity (ROE)?

Iteos Therapeutics, Inc. (ITOS) has a return on equity of -22.8% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Iteos Therapeutics, Inc.'s free cash flow?

Iteos Therapeutics, Inc. (ITOS) generated -$99.8M in free cash flow during fiscal year 2024. This represents a 6.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Iteos Therapeutics, Inc.'s operating cash flow?

Iteos Therapeutics, Inc. (ITOS) generated -$98.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Iteos Therapeutics, Inc.'s total assets?

Iteos Therapeutics, Inc. (ITOS) had $687.0M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Iteos Therapeutics, Inc.'s capital expenditures?

Iteos Therapeutics, Inc. (ITOS) invested $1.6M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Iteos Therapeutics, Inc. spend on research and development?

Iteos Therapeutics, Inc. (ITOS) invested $145.4M in research and development during fiscal year 2024.

How many shares does Iteos Therapeutics, Inc. have outstanding?

Iteos Therapeutics, Inc. (ITOS) had 37M shares outstanding as of fiscal year 2024.

What is Iteos Therapeutics, Inc.'s current ratio?

Iteos Therapeutics, Inc. (ITOS) had a current ratio of 12.62 as of fiscal year 2024, which is generally considered healthy.

What is Iteos Therapeutics, Inc.'s debt-to-equity ratio?

Iteos Therapeutics, Inc. (ITOS) had a debt-to-equity ratio of 0.16 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Iteos Therapeutics, Inc.'s return on assets (ROA)?

Iteos Therapeutics, Inc. (ITOS) had a return on assets of -19.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Iteos Therapeutics, Inc.'s cash runway?

Based on fiscal year 2024 data, Iteos Therapeutics, Inc. (ITOS) had $142.1M in cash against an annual operating cash burn of $98.2M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Iteos Therapeutics, Inc.'s Altman Z-Score?

Iteos Therapeutics, Inc. (ITOS) has an Altman Z-Score of 2.87, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Iteos Therapeutics, Inc.'s Piotroski F-Score?

Iteos Therapeutics, Inc. (ITOS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Iteos Therapeutics, Inc.'s earnings high quality?

Iteos Therapeutics, Inc. (ITOS) has an earnings quality ratio of 0.73x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Iteos Therapeutics, Inc.?

Iteos Therapeutics, Inc. (ITOS) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.